Dopamine Receptors Modulate Cytotoxicity of Natural Killer Cells via cAMP-PKA-CREB Signaling Pathway

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Zhao, Wei ^a   Huang, Yan ^a   Liu, Zhan ^a   Cao, Bei Bei ^a   Peng, Yu Ping ^a   Qiu, Yi Hua ^a  

^a NANTONG MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR; DOPAMINE RECEPTOR; FORSKOLIN; HALOPERIDOL; MESSENGER RNA; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; QUINPIROLE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; MOUSE; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ADENYLATE CYCLASE; ANIMALS; BENZAZEPINES; CELL LINE, TUMOR; COLFORSIN; CYCLIC AMP; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYTOTOXICITY, IMMUNOLOGIC; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; ENZYME ACTIVATORS; GENE EXPRESSION; ISOQUINOLINES; KILLER CELLS, NATURAL; MICE, INBRED ICR; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; QUINPIROLE; RECEPTORS, DOPAMINE D3; RECEPTORS, DOPAMINE D4; RECEPTORS, DOPAMINE D5; SECOND MESSENGER SYSTEMS; SULFONAMIDES;

MUS;

EID: 84879057802     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065860     Document Type: Article

References (41)

1. Huang Y, Qiu AW, Peng YP, Liu Y, Huang HW, et al. (2010) Roles of Dopamine Receptor Subtypes in Mediating Modulation of T Lymphocyte Function. Neuroendocrino Lett 31: 101-110.
2. Hasko G, Szabo C, Nemeth ZH, Deitch EA, (2002) Dopamine suppresses IL-12 p40 production by lipopolysaccharide-stimulated macrophages via a beta-adrenoceptor-mediated mechanism. J Neuroimmunol 122: 34-39.
3. Ghosh MC, Mondal AC, Basu S, Banerjee S, Majumder J, et al. (2003) Dopamine inhibits cytokine release and expression of tyrosine kinases, Lck and Fyn in activated T cells. Int Immunopharmacol 3: 1019-1026.
4. Carr L, Tucker A, Fernandez-Botran R, (2003) In vivo administration of L-dopa or dopamine decreases the number of splenic IFN gamma-producing cells. J Neuroimmunol 137: 87-93.
5. Basu S, Dasgupta PS, Ray MR, Lahiri T, (1992) Stimulation of NK activity in Ehrlich ascites carcinoma-bearing mice following dopamine treatment. Biog Amines 8: 191-197.
6. Teunis MA, Heijnen CJ, Cools AR, Kavelaars A, (2004) Reduced splenic natural killer cell activity in rats with hyperreactive dopaminergic system. Psychoneuroendocrinology 29: 1058-1064.
7. Kavelaars A, Cobelens PM, Teunis MA, Heijnen CJ, (2005) Changes in innate and acquired immune responses in mice with targeted deletion of dopamine transporter gene. J Neuroimmunol 161: 162-168.
8. Vallone D, Picetti R, Borrelli E, (2000) Structure and function of dopamine receptors. Neurosci Biobehav Rev 24: 125-132.
9. Zawilska JB, (2003) Dopamine receptors-structure, characterization and function. Postepy Hig Med Dosw 57: 293-322.
10. Kirillova GP, Hrutkay RJ, Shurin MR, Shurin GV, Tourkova IL, et al. (2008) Dopamine receptors in human lymphocytes: Radioligand binding and quantitative RT-PCR assays. J Neurosci Methods 174: 272-280.
11. McKenna F, McLaughlin PJ, Lewis BJ, Sibbring GC, Cummerson JA, et al. (2002) Dopamine receptor expression on human T- and B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study. J Neuroimmunol 132: 34-40.
12. Mignini F, Tomassoni D, Traini E, Amenta F, (2009) Dopamine, vesicular transporters and dopamine receptor expression and localization in rat thymus and spleen. J Neuroimmunol 206: 5-13.
13. Meredith EJ, Holder MJ, Rosen A, Lee AD, Dyer MJ, et al. (2006) Dopamine targets cycling B cells independent of receptors/transporter for oxidative attack: Implications for non-Hodgkin's lymphoma. Proc Natl Acad Sci 103: 13485-13490.
14. Saha B, Mondal AC, Majumder J, Basu S, Dasgupta PS, (2001) Physiological concentrations of dopamine inhibit the proliferation and cytotoxicity of human CD4+ and CD8+ T cells in vitro: a receptor-mediated mechanism. Neuroimmunomodulation 9: 23-33.
15. Cosentino M, Fietta AM, Ferrari M, Rasini E, Bombelli R, et al. (2007) Human CD4+CD25+ regulatory T cells selectively express tyrosine hydroxylase and contain endogenous catecholamines subserving an autocrine/paracrine inhibitory functional loop. Blood 109: 632-642.
16. Kipnis J, Cardon M, Avidan H, Lewitus GM, Mordechay S, et al. (2004) Dopamine, through the extracellular signal-regulated kinase pathway, downregulates CD4+CD25+ regulatory T-cell activity: implications for neurodegeneration. J Neurosci 24: 6133-6143.
17. Besser MJ, Ganor Y, Levite M, (2005) Dopamine by itself activates either D2, D3 or D1/D5 dopaminergic receptors in normal human T-cells and triggers the selective secretion of either IL-10, TNF-alpha or both. J Neuroimmunol 169: 161-171.
18. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG, (1998) Dopamine receptors: from structure to function. Physiol Rev 78: 189-225.
19. Pacheco R, Prado CE, Barrientos MJ, Bernales S, (2009) Role of dopamine in the physiology of T-cells and dendritic cells. J Neuroimmunol 216: 8-19.
20. Papadopoulos NG, Dedoussis GVZ, Spanakos G, Gritzapis AD, Baxevanis CN, et al. (1994) An improved fluorescence assay for the determination of lymphocyte-mediated cytotoxicity using flow cytometry. J Immunol Meth 177: 101-111.
21. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using Real-Time quantitative PCR and the 2-ΔΔCt method. Methods 25: 402-408.
22. Ilani T, Strous RD, Fuchs S, (2004) Dopaminergic regulation of immune cells via D3 dopamine receptor: a pathway mediated by activated T cells. Faseb J 18: 1600-1602.
23. Watanab Y, Nakayama T, Nagakubo D, Hieshima K, Jin Z, et al. (2006) Dopamine selectively induces migration and homing of naïve CD8+ T cells via dopamine receptor D3. J Immunol 176: 848-856.
24. Nakano K, Higashi T, Hashimoto K, Takagi R, Tanaka Y, et al. (2008) Antagonizing dopamine D1-like receptor inhibits Th17 cell differentiation: preventive and therapeutic effects on experimental autoimmune encephalomyelitis. Biochem Biophys Res Commun 373: 286-291.
25. Monsma Jr FJ, Mahan LC, McVittie LD, Gerfen CR, Sibley DR, (1990) Molecular cloning and expression of a D1 dopamine receptor linked to adenylyl cyclase activation. Proc Natl Acad Sci 87: 6723-6727.
26. Jackson DM, Westlind-Danielsson A, (1994) Dopamine receptors: molecular biology, biochemistry and behavioural aspects. Pharmacol Ther 64: 291-370.
27. Robinson SW, Caron MG, (1997) Selective inhibition of adenylyl cyclase type V by the dopamine D3 receptor. Mol Pharmacol 52: 508-514.
28. Yao WD, Spealman RD, Zhang J, (2008) Dopaminergic Signaling in Dendritic Spines. Biochem Pharmacol 75: 2055-2069.
29. Santanavanich C, Ebadi M, Govitrapong P, (2005) Dopamine receptor activation in bovine pinealocyte via a cAMP-dependent transcription pathway. J Pineal Res 38: 170-175.
30. Yujnovsky I, Hirayama J, Doi M, Borrelli E, Sassone-Corsi P, (2006) Signaling mediated by the dopamine D2 receptor potentiates circadian regulation by CLOCK:BMAL1. Proc Natl Acad Sci 103: 6386-6391.
31. Iizuka Y, Sei Y, Weinberger DR, Straub RE, (2007) Evidence that the BLOC-1 protein dysbindin modulates dopamine D2 receptor internalization and signaling but not D1 internalization. J Neurosci 27: 12390-12395.
32. de Leeuw van Weenen JE, Parlevliet ET, Maechler P, Havekes LM, Romijn JA, et al. (2010) The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells. Biochem Pharmacol 79: 1827-1836.
33. Ramstad C, Sundvold V, Johansen HK, Lea T, (2000) cAMP-dependent protein kinase (PKA) inhibits T cell activation by phosphorylating ser-43 of raf-1 in the MAPK/ERK pathway. Cell Signal 12: 557-563.
34. Harada Y, Miyatake S, Arai K, Watanabe S, (1999) Cyclic AMP inhibits the activity of c-Jun N-terminal kinase (JNKp46) but not JNKp55 and ERK2 in human helper T lymphocytes. Biochem. Biophys Res Commun 266: 129-134.
35. Vang T, Torgersen KM, Sundvold V, Saxena M, Levy FO, et al. (2001) Activation of the COOH-terminal Src kinase (Csk) by cAMP-dependent protein kinase inhibits signaling through the T cell receptor. J Exp Med 193: 497-507.
36. Hershfield MS, (2005) New insights into adenosine-receptor-mediated immunosuppression and the role of adenosine in causing the immunodeficiency associated with adenosine deaminase deficiency. Eur J Immunol 35: 25-30.
37. Jimenez JL, Punzon C, Navarro J, Munoz-Fernandez MA, Fresno M, (2001) Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor-kappaB and nuclear factor of activated T cells activation. J Pharmacol Exp Ther 299: 753-759.
38. Aandahl EM, Moretto WJ, Haslett PA, Vang T, Bryn T, et al. (2002) Inhibition of antigen-specific T cell proliferation and cytokine production by protein kinase A type I. J Immunol. 169: 802-808.
39. Neumann M, Grieshammer T, Chuvpilo S, Kneitz B, Lohoff M, et al. (1995) RelA/p65 is a molecular target for the immunosuppressive action of protein kinase A. EMBO J. 14: 1991-2004.
40. Beck GCH, Brinkkoetter P, Hanusch C, Schulte J, van Ackern K, et al. (2004) Clinical review: immunomodulatory effects of dopamine in general inflammation. Crit Care 8: 485-491.
41. Yang M, Zhang H, Voyno-Yasenetskaya T, Ye RD, (2003) Requirement of Gbetagamma and c-Src in D2 dopamine receptor-mediated nuclear factor-kappaB activation. Mol Pharmacol 64: 447-455.